We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Tissue Spacers Reduce Risk of Rectal Injury

By HospiMedica International staff writers
Posted on 19 May 2011
Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal radiation dose for prostate cancer patients receiving radiation therapy, according to a new study.

Researchers at the Cancer Center of Irvine (CA, USA) conducted a study involving 34 prostate carcinoma patients that were injected with a tissue spacer compound to increase the separation between the prostate and the rectum during the radiation therapy they were receiving. More...
The patients were imaged via magnetic resonance imaging (MRI) preinjection, postinjection, and every two weeks until the end of treatment to monitor any changes.

The researchers found that the spacer generated an additional one centimeter (on average) separation between the prostate and rectum, resulting in a significant reduction in the rectal dose administered and causing very little damage to the rectum. The reductions in severe rectal radiation burns--the most serious risk of injury from the radiation--were essentially eliminated. This enabled the radiation oncologists to increase the dose to the posterior prostate without concern of damaging the rectum. The study was presented at the Cancer Imaging and Radiation Therapy Symposium, held during April 2011 in Atlanta (GA, USA).

"Removing rectal injury from the treatment essentially makes radiation therapy the treatment of choice for prostate cancer," said senior author and study presenter Kenneth Tokita, MD. "The ability to reach almost perfect cure rates and minimal injury is the dream of all cancer specialists. We are now wondering where else this may benefit cancer patients in radiation therapy treatments."

Treatment for prostate cancer may involve active surveillance (monitoring for tumor progress or symptoms), surgery (radical prostatectomy), radiation therapy including brachytherapy and external beam radiation therapy, high-intensity focused ultrasound (HIFU), chemotherapy, cryosurgery, hormonal therapy, or some combination. Which option is best depends on the stage of the disease, the Gleason score, and the prostate-specific antigen (PSA) level. Other important factors are age, general health, and patient views about potential treatments and their possible side effects.

Related Links:
Cancer Center of Irvine



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.